Filtered By:
Source: The American Journal of Medicine

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 259 results found since Jan 2013.

Vascular Risk Factors, Cardiovascular Disease, and Restless Legs Syndrome in Men
Conclusions: The restless legs syndrome prevalence among US male physicians is similar to that of men of the same age group in other western countries. A history of diabetes is the most consistent risk factor associated with restless legs syndrome. Prevalent stroke and myocardial infarction are related to restless legs syndrome prevalence.
Source: The American Journal of Medicine - February 15, 2013 Category: Journals (General) Authors: Anke C. Winter, Klaus Berger, Robert J. Glynn, Julie E. Buring, J. Michael Gaziano, Markus Schürks, Tobias Kurth Tags: Clinical research studies Source Type: research

ALTITUDE Trial and Dual RAS Blockade: The Alluring but Soft Science of the Surrogate End Point
On December 20, 2011, the large, landmark Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) was terminated on the basis of the recommendations of the Data and Safety Monitoring Board. The ALTITUDE was designed to evaluate the effects of aliskiren versus placebo on top of an angiotensin receptor blocker or an angiotensin-converting enzyme inhibitor in more than 8000 patients with type II diabetes and renal impairment. An increased incidence of hypotension, hyperkalemia, renal complications, and nonfatal stroke (HR = 1.25; 95% CI 0.98-1.60; P = .07) was observed in the aliskiren arm during the follow...
Source: The American Journal of Medicine - January 17, 2013 Category: Journals (General) Authors: Franz H. Messerli, Sripal Bangalore Tags: Commentary Source Type: research

Ineligibility for Anticoagulation in Patients with Atrial Fibrillation
Abstract: Although anticoagulation therapy markedly reduces the risk of stroke in patients with atrial fibrillation, up to 50% of these patients are deemed ineligible for anticoagulation. In this manuscript we provide a framework to assess the net clinical benefit of anticoagulation in patients with atrial fibrillation with an increased risk of bleeding. We also review recent data related to the novel oral anticoagulants targeting thrombin or factor Xa, and discuss how the introduction of these agents raises the distinction between eligibility for vitamin K antagonist therapy specifically, and eligibility for anticoagulation in general.
Source: The American Journal of Medicine - January 17, 2013 Category: Journals (General) Authors: Ian del Conde, Jonathan L. Halperin Tags: Reviews Source Type: research

CHADS2 Score, Statin Therapy, and Risks of Atrial Fibrillation
This study aimed to evaluate the efficacy of statin treatment for atrial fibrillation prevention in elderly patients with hypertension, and to determine if comorbidity or CHADS2 (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke or transient ischemic attack) score can predict the effectiveness of statin treatment. Methods: Patients aged ≥65 years with hypertension were identified from a National Health Insurance research database (a systemic sampling from 2000 to 2009 with a total of 1,000,000 subjects). Medical records of 27,002 patients were used in this study, in which 2400 (8....
Source: The American Journal of Medicine - January 17, 2013 Category: Journals (General) Authors: Chen-Ying Hung, Ching-Heng Lin, El-Wui Loh, Chih-Tai Ting, Tsu-Juey Wu Tags: Clinical research studies Source Type: research